Previous 10 | Next 10 |
2023-05-09 14:24:02 ET Xeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executiv...
2023-05-09 07:03:17 ET Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q1 GAAP EPS of -$0.12 beats by $0.05 . Revenue of $33.2M (+51.5% Y/Y) beats by $2.43M . FY2023 Outlook : Total revenue of $135M-$165M vs. consensus of $146.9M; cash utilization fro...
Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M; cash utilization from operating activities of $57M-$77M; ...
2023-05-08 12:35:57 ET Xeris Pharmaceuticals ( NASDAQ: XERS ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.15 (+40.0% Y/Y) and the consensus Revenue Estimate is $30.77M (+40.4% Y/Y). Over the la...
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
2023-04-18 07:42:03 ET Xeris Biopharma ( NASDAQ: XERS ) said that the U.S. Patent and Trademark Office issued a patent covering its XeriSol formulations. The Patent Number 11,590,205 is titled 'Methods for producing stable therapeutic glucagon formulations in aprotic pola...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Paten...
--News Direct-- Xeris Biopharma chairman and CEO Paul Edick joins Proactive's Natalie Stoberman to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals for further XeriJect development. Edick says the agreement will see Xeris using its proprietary drug...
2023-03-30 07:17:56 ET Xeris Biopharma Holdings ( NASDAQ: XERS ) announced Thursday an agreement with Regeneron Pharmaceuticals ( REGN ) to use its drug-formulation platform, XeriJect, to develop monoclonal antibodies for subcutaneous delivery. Per the terms, Chicago, ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collab...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...